# Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

> **NCT00826540** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 83 (actual)

## Conditions studied

- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage IV Colon Cancer
- Stage IV Rectal Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00826540
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-01
- **Final completion:** 2014-02
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826540, "Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00826540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*